Rocket Pharmaceuticals, Inc. (RCKT): Price and Financial Metrics
RCKT Price/Volume Stats
| Current price | $23.48 | 52-week high | $32.53 |
| Prev. close | $23.68 | 52-week low | $14.89 |
| Day low | $23.32 | Volume | 551,300 |
| Day high | $23.93 | Avg. volume | 715,169 |
| 50-day MA | $27.36 | Dividend yield | N/A |
| 200-day MA | $22.98 | Market Cap | 2.13B |
RCKT Stock Price Chart Interactive Chart >
Rocket Pharmaceuticals, Inc. (RCKT) Company Bio
Rocket Pharmaceuticals, Inc., formerly Inotek Pharmaceuticals Corporation, is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapies for glaucoma and other diseases of the eye.
Latest RCKT News From Around the Web
Below are the latest news stories about ROCKET PHARMACEUTICALS INC that investors may wish to consider to help them evaluate RCKT as an investment opportunity.
11 Most Promising Biotech Stocks to Buy According to AnalystsIn this article, we will take a look at the 11 most promising biotech stocks to buy according to analysts. To skip our analysis of the recent trends, and market activity, you can go directly to see the 5 Most Promising Biotech Stocks to Buy According to Analysts. The biotech industry is making a resurgence […] |
Rocket Pharmaceuticals Appoints R. Keith Woods to Board of DirectorsCRANBURY, N.J., December 12, 2023--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a leading late-stage biotechnology company advancing an integrated and sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced the appointment of R. Keith Woods as an independent, non-executive director to its Board of Directors. Mr. Woods is a seasoned executive with more than 30 years of experience spanning commercialization, global operations, business strategy and supply |
Billionaire Lee Ainslie’s Top 10 Stock PicksIn this article, we will take a look at Billionaire Lee Ainslie’s top 10 stock picks. For more Ainslie’s stocks, head on over to Billionaire Lee Ainslie’s Top 5 Stock Picks. Hedge fund managers are known for investing in various asset classes in the race to unlock value in the market. But not Lee Ainslie, a […] |
Rocket (RCKT) Surges 40% in 3 Months on Regulatory UpdatesRocket (RCKT) gains 40% in three months on positive regulatory updates on its key candidates. |
Wall Street Analysts See a 167.09% Upside in Rocket Pharmaceuticals (RCKT): Can the Stock Really Move This High?The consensus price target hints at a 167.1% upside potential for Rocket Pharmaceuticals (RCKT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term. |
RCKT Price Returns
| 1-mo | -12.62% |
| 3-mo | -11.60% |
| 6-mo | 36.83% |
| 1-year | 21.97% |
| 3-year | -43.20% |
| 5-year | 38.93% |
| YTD | -21.65% |
| 2023 | 53.14% |
| 2022 | -10.35% |
| 2021 | -60.19% |
| 2020 | 140.95% |
| 2019 | 53.58% |
Loading social stream, please wait...